Evidence map›Paper›PMID 30220971›Full record

ArticleOncotarget2018

Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.

Endang Nuryadi, Yasushi Sasaki, Yoshihiko Hagiwara, Tiara Bunga Mayang Permata, Hiro Sato, Shuichiro Komatsu, Yuya Yoshimoto, Kazutoshi Murata, Ken Ando, Nobuteru Kubo and 13 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Mutation Analysis of Radioresistant Early-Stage Cervical Cancer.International journal of molecular sciences · 2021
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 2 countries.

Endang Nuryadi *Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yasushi Sasaki *Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan.
Yoshihiko Hagiwara *Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Tiara Bunga Mayang PermataDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Hiro SatoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Shuichiro KomatsuDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yuya YoshimotoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Kazutoshi MurataDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Ken AndoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Nobuteru KuboDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Noriyuki OkonogiDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yosuke TakakusagiDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Akiko AdachiDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Mototaro IwanagaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Keisuke TsuchidaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Tomoaki TamakiDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Shin-Ei NodaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yuka HirotaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Atsushi ShibataEducation and Research Support Center, Gunma University Graduate School of Medicine, Gunma, Japan.
Tatsuya OhnoGunma University Heavy Ion Medical Center, Gunma, Japan.
Takashi TokinoDepartment of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan.
Takahiro OikeDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Takashi NakanoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Gunma University · JPGunma University Hospital · JPSapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy is an essential component of cancer therapy. Despite advances in cancer genomics, the mutation signatures of radioresistant tumors have not yet been fully elucidated. To address this issue, we analyzed a unique set of clinical specimens from a uterine cervical cancer that repeatedly locally recurred after multiple rounds of radiotherapy. Exon sequencing of 409 cancer-related genes in the treatment-naïve tumor and the tumors that recurred after initial and secondary radiotherapy identified (i) activating mutations in

Indexed as

KRASnext-generation sequencingradioresistanceSMAD4uterine cervical cancer

Identifiers

PMID30220971
PMCPMC6135691
OpenAlexW2888676047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.